Personally think this one is expensive. I do invest in most of biotech IPOs I can get my hand on if priced properly or has great management. Find this one is expensive compared too development stage it is in currently. Has potential but likely stag at 20 to 25% at most.
Pass for me
GLTAH if you are bidding
